Study proves safety and effectiveness of novel radionuclide therapy for neuroendocrine neoplasms
A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some patients.
Source: news-medical.net